Analysts Estimate Report : What to Look Out for Biogen (NASDAQ:BIIB)

0
950

Earnings results for Biogen (NASDAQ:BIIB)

Biogen Inc. is expected* to report earnings on 10/21/2020 before market open. The report will be for the fiscal Quarter ending Sep 2020. According to Zacks Investment Research, based on 27 analysts’ forecasts, the consensus EPS forecast for the quarter is $8.07. The reported EPS for the same quarter last year was $9.17.

Biogen last released its quarterly earnings data on July 22nd, 2020. The biotechnology company reported $10.26 earnings per share for the quarter, beating analysts’ consensus estimates of $8.03 by $2.23. The business earned $3.68 billion during the quarter, compared to analysts’ expectations of $3.44 billion. Biogen has generated $33.57 earnings per share over the last year and currently has a price-to-earnings ratio of 7.8. Biogen has confirmed that its next quarterly earnings report will be published on Wednesday, October 21st, 2020.

Analyst Opinion on Biogen (NASDAQ:BIIB)

31 Wall Street analysts have issued ratings and price targets for Biogen in the last 12 months. Their average twelve-month price target is $311.82, predicting that the stock has a possible upside of 16.73%. The high price target for BIIB is $396.00 and the low price target for BIIB is $228.00. There are currently 4 sell ratings, 16 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of “Hold.”

Biogen has received a consensus rating of Hold. The company’s average rating score is 2.23, and is based on 11 buy ratings, 16 hold ratings, and 4 sell ratings. According to analysts’ consensus price target of $311.82, Biogen has a forecasted upside of 16.7% from its current price of $267.12. Biogen has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Dividend Strength: Biogen (NASDAQ:BIIB)

Biogen does not currently pay a dividend. Biogen does not have a long track record of dividend growth.

Insiders buying/selling: Biogen (NASDAQ:BIIB)

In the past three months, Biogen insiders have not sold or bought any company stock. Only 0.54% of the stock of Biogen is held by insiders. 83.74% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of Biogen (NASDAQ:BIIB

Earnings for Biogen are expected to decrease by -13.86% in the coming year, from $34.64 to $29.84 per share. The P/E ratio of Biogen is 7.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 19.71. The P/E ratio of Biogen is 7.82, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.61. Biogen has a PEG Ratio of 1.62. PEG Ratios above 1 indicate that a company could be overvalued. Biogen has a P/B Ratio of 3.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here